Reach Us +12 184512974

Abstract

Oral Bioavailability enhancement of Ganciclovir by Chitosan Nanoparticles: Pharmacokinetics Studies

Ganciclovir (GCV), an acyclovir analogue,proved to have excellent antiviral activity against human Cytomegalovirus (CMV), a leading cause of congenital infections worldwide. Ganciclovir (GCV), given intravenously (i.v.) at 5 mg/kg of body weight once daily, or orally as capsules at 1,000 mg three times a day (TID), is the standard drug regimen for both the treatment and prevention of CMV disease. . However, i.v. GCV is an inconvenient drug regimen for long-term use, requiring i.v. catheters and might leads to sepsis. Although GCV capsules are more convenient, the low relative bioavailability (6%) limits the concentrations in serum


Author(s):

Rajendra Kotadia



Abstract | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

buca escort karşıyaka escort

https://wowcappadocia.com
https://cappadocia-hotels.com
https://caruscappadocia.com
https://brothersballoon.com
https://balloon-rides.net

https://paperio-live.com

rolex replica

https://agario.red

https://naughtyworms.com

melbet
https://sekillinickyazi.com/